Clinical Trials Browser

Recurrence × Specimen Handling × 90 days × Clear all

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

Clinical Trials

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer